Benefit of CoQ-10 in Patients on Statins

Stony Brook University

Status: Completed

Conditions: Weakness; Soreness; Fatigue; Pain

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Co-enzyme Q-10

Study type: Interventional

Funder types: Other

Identifiers

NCT00997269

2008-0436

AT004204

Details and patient eligibility

About

This study will investigate whether a supplement called co-enzyme Q10 can help ease or eliminate some of the side effects that result from taking statin medications. These side effects include muscle pain, fatigue or muscle cramping.

Full description

Specific Aim 1: to demonstrate that supplementation with coQ10 in patients treated with statins ameliorates symptoms of muscle pain and fatigue and improves energy metabolism and muscle function.

This objective will be achieved in a randomized, placebo-controlled double blind trial by assessing the degree of muscle symptoms and interference of pain with daily activities, aerobic capacity, and muscle function before and after supplementation with either coQ10 or placebo in groups of statin-treated subjects.

Specific Aim 2: to examine changes at a molecular/cellular level that are associated with improved pain and muscle function in statin-treated subjects supplemented with coQ10.

This aim will be addressed by analyzing muscle biopsies taken from statin-treated patients before and after supplementation with coQ10 or placebo.

Enrollment: 37 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult men and women 21 years and older taking statin medications for hyperlipidemia under the current National Cholesterol Education Program guidelines (NCEP III) and complaining of myopathic symptoms.

Exclusion criteria

1. diagnosis of cancer;
2. acute illness of any sort;
3. hemoglobin less than 12,
4. creatinine greater than 1.5 mg/dl;
5. liver dysfunction as evidenced by elevations in transaminases 3-fold higher than upper limit of normal;
6. use of certain medications or nutritional supplements within the past month;
7. untreated hypertension (diastolic BP> 100 mm HG);
8. diagnosis of diabetes mellitus (fasting blood glucose > 126 mg/dl);
9. untreated hypothyroidism;
10. overt congestive heart failure (by physical exam);
11. active inflammatory diseases such as rheumatoid arthritis, lupus, etc.,
12. bleeding disorders;
13. history of adverse reactions besides myopathy associated with the use of statins;
14. any previous adverse reaction to coQ10 or to multivitamin supplements containing coQ10;
15. plasma CPK levels > 3 times the upper normal limit; OR
16. congenital myopathies and/or neuromuscular degenerative diseases.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

37 participants in 2 patient groups, including a placebo group

CoQ-10 supplementation

Experimental group

Treatment:

Dietary Supplement: Co-enzyme Q-10

CoQ-10 placebo supplementation

Placebo Comparator group

Treatment:

Dietary Supplement: Placebo